Shanmuga Hospital Limited, formerly known as Shanmuga Hospital Private Limited, has announced its unaudited financial results for the half-year ended September 30, 2025. The company, which operates in the hospital and healthcare services sector, has reported a net profit of ₹201.13 crore for the period.

Financial Highlights

Key Financial Metrics

The company's performance shows a mixed picture when compared to previous periods:

• Net profit of ₹201.13 crore, up from ₹181.38 crore in the previous period
• However, net profit is down from ₹239.29 crore in the corresponding period last year
• Total expenses stood at ₹2,201.68 crore
• Cost of consumption was the largest expense at ₹813.05 crore
• Other expenses amounted to ₹828.12 crore
• Employee benefits expense was ₹366.76 crore

IPO Proceeds Utilization

Shanmuga Hospital Limited completed the full utilization of its IPO proceeds of ₹2,061.72 crore during the reporting period. The funds were allocated as follows:

The company reported that the opening unutilized IPO proceeds of ₹1,115.50 crore as of April 1, 2025, were fully utilized during the first half of the year (April 2025 to September 2025) towards the object of the issue.

Balance Sheet Overview

As of September 30, 2025, Shanmuga Hospital Limited's balance sheet shows:

The Board of Directors approved these results at their meeting held on November 12, 2025. The company operates only in one business segment – Hospital and Healthcare Services.

Shanmuga Hospital Limited continues to focus on its core operations in the healthcare sector, with its financial results reflecting the ongoing challenges and opportunities in the industry. The company's full utilization of its IPO proceeds indicates a focus on expansion and operational improvements.

Shanmuga Hospital Limited , a multi-specialty healthcare provider based in Salem, Tamil Nadu, has issued a correction to its investor presentation, significantly revising the reported number of inpatients and outpatients for the fiscal year 2024-25.

Key Corrections

The company has made the following adjustments to its patient volume data:

This correction represents a substantial increase in both inpatient and outpatient numbers, with outpatient figures showing a particularly significant revision.

Company Performance

Despite the data correction, Shanmuga Hospital Limited reported solid financial performance for FY2024-25:

• Revenue: ₹4,785.33 lakhs (11.20% year-over-year growth)
• EBITDA: ₹817.09 lakhs (2.80% year-over-year decline)
• PAT: ₹420.67 lakhs (19.80% year-over-year decline)

The hospital maintained an average occupancy rate of 49.78% across its 140 operational beds out of a total capacity of 150+ beds.

Strategic Initiatives

Shanmuga Hospital Limited has outlined several strategic initiatives to drive future growth:

1. Launching a dedicated Nephro Care Center
2. Adding 50 inpatient beds to increase capacity
3. Introducing renal transplant services
4. Relocating the Outpatient Department (OPD) to newly developed premises
5. Developing the "Shanmuga Health App" for improved patient access to services

Company Background

Established in 1981 and recently listed on the BSE SME platform in 2025, Shanmuga Hospital Limited has been providing healthcare services in Salem for over four decades. The hospital offers advanced medical and surgical care through specialized units, including Intensive Care, Neonatal Intensive Care, Oncology, Cardiac, and Emergency departments.

Management Commentary

While specific management comments on the data revision were not provided, the company stated in its LODR filing, "The revised Presentation after carrying out the above changes is enclosed below. The said Presentation is also being disseminated on the Company's website at www.shanmugahospital.com ."

This correction underscores the importance of accurate reporting in investor communications and highlights the significant patient volume handled by Shanmuga Hospital Limited. The revised figures suggest a stronger market position and higher utilization of the hospital's services than initially reported, which may be of interest to investors and stakeholders in assessing the company's performance and growth potential.